Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Pancrelipase controlled-release - Digestive Care

Next Previous
Search
Drug Profile

Pancrelipase controlled-release - Digestive Care

Alternative Names: PANCRECARB® MS-16; Pancrelipase delayed release capsules - Digestive Care; Pertzye; Pertzyme

Latest Information Update: 02 Oct 2021

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Digestive Care
  • Developer Chiesi USA; Digestive Care
  • Class Pancreatic enzymes
  • Mechanism of Action Enzyme replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Exocrine pancreatic insufficiency

Most Recent Events

  • 14 Jul 2017 Registered for Exocrine pancreatic insufficiency (In adolescents, In adults, In children, In infants) in USA (PO)
  • 01 Dec 2016 Mayo Clinic and Digestive Care initiate enrolment in a phase I/II trial for Exocrine pancreatic insufficiency (unresectable pancreatic cancer associated) in USA (NCT02985801)
  • 12 Oct 2016 Launched for Exocrine pancreatic insufficiency (In infants) in USA in October 2016 (PO, 4000 USP lipase units/capsule)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top